<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Health Qual Life Outcomes</journal-id><journal-id journal-id-type="iso-abbrev">Health Qual Life Outcomes</journal-id><journal-title-group><journal-title>Health and Quality of Life Outcomes</journal-title></journal-title-group><issn pub-type="epub">1477-7525</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24886671</article-id><article-id pub-id-type="pmc">4029890</article-id><article-id pub-id-type="publisher-id">1477-7525-12-69</article-id><article-id pub-id-type="doi">10.1186/1477-7525-12-69</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Could baseline health-related quality of life (QoL) predict overall survival in metastatic colorectal cancer? The results of the GERCOR OPTIMOX 1 study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Diouf</surname><given-names>Momar</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>diouf.momar@chu-amiens.fr</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Chibaudel</surname><given-names>Benoist</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>benoist.chibaudel@sat.aphp.fr</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Filleron</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>Filleron.Thomas@claudiusregaud.fr</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Tournigand</surname><given-names>Christophe</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>christophe.tournigand@sat.aphp.fr</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Hug de Larauze</surname><given-names>Marine</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>marine.hugdelarauze@gercor.com.fr</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Garcia-Larnicol</surname><given-names>Marie-Line</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>marie-line.garcia@sat.ap-hop-paris.fr</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Dumont</surname><given-names>Sarah</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>SARAHNDUMONT@YAHOO.FR</email></contrib><contrib contrib-type="author" id="A8"><name><surname>Louvet</surname><given-names>Christophe</given-names></name><xref ref-type="aff" rid="I7">7</xref><email>CHRISTOPHE.LOUVET@IMM.FR</email></contrib><contrib contrib-type="author" id="A9"><name><surname>Perez-Staub</surname><given-names>Nathalie</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>nathalie.perez@sat.aphp.fr</email></contrib><contrib contrib-type="author" id="A10"><name><surname>Hadengue</surname><given-names>Alexandra</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>alexandra.hadengue@gercor.com.fr</email></contrib><contrib contrib-type="author" id="A11"><name><surname>de Gramont</surname><given-names>Aimery</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>aimery.de-gramont@sat.aphp.fr</email></contrib><contrib contrib-type="author" id="A12"><name><surname>Bonnetain</surname><given-names>Franck</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I4">4</xref><email>franck.bonnetain@univ-fcomte.fr</email></contrib></contrib-group><aff id="I1"><label>1</label>Direction de la Recherche Clinique et de l&#x02019;Innovation, Centre Hospitalier Universitaire Amiens, Nord, 1, Place Victor Pauchet, F-80054, Amiens, Cedex, France</aff><aff id="I2"><label>2</label>Methodology and quality of life in oncology Unit, EA 3181 CHU Besan&#x000e7;on and the Qualit&#x000e9; de Vie et Cancer clinical research platform, Dijon, France</aff><aff id="I3"><label>3</label>Department of medical oncology, H&#x000f4;pital Saint-Antoine, Assistance Publique des H&#x000f4;pitaux de Paris, UPMC Paris VI, Paris, France</aff><aff id="I4"><label>4</label>Oncology Multidisciplinary Research Group (GERCOR), Paris, France</aff><aff id="I5"><label>5</label>Biostatistics Unit, Claudius R&#x000e9;gaud Institute, Toulouse, France</aff><aff id="I6"><label>6</label>Department of medical oncology, H&#x000f4;pital Henri Mondor, Assistance Publique des H&#x000f4;pitaux de Paris, Cr&#x000e9;teil, Paris, France</aff><aff id="I7"><label>7</label>Department of medical oncology, Institut Mutualiste Montsouris, Paris, France</aff><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>13</day><month>5</month><year>2014</year></pub-date><volume>12</volume><fpage>69</fpage><lpage>69</lpage><history><date date-type="received"><day>18</day><month>10</month><year>2013</year></date><date date-type="accepted"><day>29</day><month>4</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2014 Diouf et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Diouf et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (
<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (
<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.hqlo.com/content/12/1/69"/><abstract><sec><title>Background</title><p>Health-related quality of life (QoL) has prognostic value in many cancers. A recent study found that the performance of prognostic systems for metastatic colorectal cancer (mCRC) were improvable. We evaluated the independent prognostic value of QoL for overall survival (OS) and its ability to improve two prognostic systems&#x02019;performance (K&#x000f6;hne and GERCOR models) for patients with mCRC.</p></sec><sec><title>Methods</title><p>The EQ-5D questionnaire was self-completed before randomization in the OPTIMOX1, a phase III trial comparing two strategies of FOLFOX chemotherapy which included 620 previously untreated mCRC patients recruited from January 2000 to June 2002 from 56 institutions in five countries. The improvement in models&#x02019; performance (after addition of QoL) was studied with Harrell&#x02019;s C-index and the net reclassification improvement.</p></sec><sec><title>Results</title><p>Of the 620 patients, 249 (40%) completed QoL datasets<bold>.</bold> The K&#x000f6;hne model could be improved by LDH, mobility and pain/discomfort; the C-index rose from 0.54 to 0.67. The associated NRI for 12-month death was 0.23 [0.05; 0.46]. Mobility and pain/discomfort could be added to the GERCOR model: the C-index varied from 0.63 to 0.68. The NRI for 12 months death was 0.35 [0.12; 0.44].</p></sec><sec><title>Conclusions</title><p>Mobility and pain dimensions of EQ5D are independent prognostic factors and could be useful for staging and treatment assignment of mCRC patients. Presented at the 2011 ASCO Annual Meeting (#3632).</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Colorectal cancer (CRC) is the third most diagnosed cancer in men and the second most diagnosed in women, with over 1.2 million new cases and 608 700 deaths worldwide in 2008
[<xref ref-type="bibr" rid="B1">1</xref>]. About up to half (20% to 50%) of CRC patients will develop metastases during the course of their disease
[<xref ref-type="bibr" rid="B2">2</xref>] and approximately 35% are diagnosed with synchronous metastases
[<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>]. Standard treatments for metastatic CRC (mCRC) are based on chemotherapy.</p><p>As is the case for many cancers, CRC staging is essential for optimal patient management. Accurate prognostication facilitates both therapeutic decisions and stratification in randomized clinical trials of cancer treatments. In CRC, the well-known TNM staging system is predominantly used
[<xref ref-type="bibr" rid="B4">4</xref>]. In mCRC, two validated prognostic classification systems can be applied: K&#x000f6;hne prognostic index
[<xref ref-type="bibr" rid="B5">5</xref>] for patients receiving front-line fluoropyrimidine mono-chemotherapy and GERCOR (Groupe Coop&#x000e9;rateur Multidisciplinaire en Oncologie) prognostic index
[<xref ref-type="bibr" rid="B6">6</xref>] for patients with oxaliplatin-based or irinotecan-based regimens. However, the models&#x02019; ability to discriminate between patients on the basis of their prognosis (as measured by the C-index
[<xref ref-type="bibr" rid="B7">7</xref>]) is still relatively modest. Thus, improvement of these prognostic indicators is required
[<xref ref-type="bibr" rid="B6">6</xref>].</p><p>In palliative care patients, the prognostic value of health-related quality of life (QoL) has been demonstrated for several types of cancer
[<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B10">10</xref>]. For mCRC patients, QoL is known to be an independent prognostic factor for overall survival (OS)
[<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. Hence, QoL is a candidate for the improvement of existing prognostic indices. Given that QoL is a multidimensional concept, there is a need to identify the QoL dimensions associated with OS for each specific type of cancer. The results of a recent study showed that social functioning (as measured with the EORTC QLQ-C30 tool) is an independent prognostic factor for survival in mCRC patients
[<xref ref-type="bibr" rid="B12">12</xref>]. The objective of the present study was to assess the independent prognostic value of QoL in mCRC and evaluate its ability to improve the K&#x000f6;hne and GERCOR prognostic indices.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Patients</title><p>Individual patient data from the OPTIMOX1 phase III trial were analysed. The 620 evaluable patients from OPTIMOX1 were recruited from January 2000 to June 2002 from 56 institutions in five countries. In this trial, the oxaliplatin stop-and-go strategy proved to be as good as a continuous oxaliplatin-based chemotherapy strategy in previously untreated mCRC patients. The trial's inclusion and exclusion criteria are detailed elsewhere
[<xref ref-type="bibr" rid="B13">13</xref>].</p></sec><sec><title>Quality of life assessment</title><p>Quality of life was self-reported by the patient using the generic EQ-5D questionnaire (also known as EuroQol)
[<xref ref-type="bibr" rid="B14">14</xref>], which has five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) rated as one of three levels ("no problems",&#x0201d;some problems" and &#x0201d;extreme problems", coded as 1, 2 and 3, respectively). The EQ-5D also includes a 100-centimetre visual analogue scale (VAS) for the self-assessment of overall health (0 = worst possible score; 100 = best possible score).</p></sec><sec><title>The GERCOR and K&#x000f6;hne prognostic indices</title><p>The K&#x000f6;hne prognostic index
[<xref ref-type="bibr" rid="B5">5</xref>] comprises four variables: performance status (PS), number of metastatic sites, alkaline phosphatase (ALP) level and white blood cell (WBC) count. The GERCOR prognostic index
[<xref ref-type="bibr" rid="B6">6</xref>] is based on two variables: PS and serum lactate dehydrogenase (LDH) level. Patients are classified into three risk groups (low, intermediate and high) in both models.</p></sec><sec><title>Statistical analysis</title><p>Demographic and clinical characteristics were summarized as frequency and percentage. In order to check whether selection bias was present, the patients&#x02019;clinical characteristics were compared (with chi-squared test or Fisher's exact test) as a function of the available QoL data at baseline.</p><p>Overall survival was defined as the time from randomization to death (regardless of the cause) or last follow-up (censored data). All randomized patients with complete QoL data were included in the statistical analysis.</p><p>Univariate and multivariate analysis were performed using Cox proportional hazards modelling, with calculation of the hazard ratio (HR) and the corresponding 95% two-sided confidence intervals (95%CI).</p><p>In order to evaluate the independent prognostic value of QoL, we built two multivariate models with backward selection. The first model included all demographic and clinical variables associated with OS (p&#x0003c;0.1) in univariate analysis. The second model included demographic, clinical and QoL variables with p&#x0003c;0.1 in univariate analysis.</p><p>Improvements in the prognostic index was evaluated by adding clinical variables (other than those used to build the prognostic index) and QoL variables (with p&#x0003c;0.1 in univariate analysis) to a model with backward selection (K&#x000f6;hne or GERCOR index being forced in the model). Patients with available QoL data for whom K&#x000f6;hne and GERCOR indices could be calculated were considered for prognostic systems&#x02019; improvement.</p><p>The models were compared by calculating the Schemper statistic
[<xref ref-type="bibr" rid="B15">15</xref>] and Harrell&#x02019;s C index
[<xref ref-type="bibr" rid="B7">7</xref>]. The Schemper statistic is equivalent to R<sup>2</sup> in linear regression and quantifies the proportion of the survival variability that is explained by the model. Briefly, the higher the Schemper statistic is, the more accurate the OS predictions would be. Harrell&#x02019;s C index estimates discriminate capability, i.e. the ability to distinguish between high-risk and low-risk patients. The C-index varies from 0.5 (no discrimination) to 1 (perfect discrimination). Optimism-corrected C-index was calculated using 200 bootstrap replications.</p><p>Category-free net reclassification improvement
[<xref ref-type="bibr" rid="B16">16</xref>] (NRI) was also calculated at various moments (12, 24 and 36 months), in order to evaluate the additional utility of QoL domains and other clinical factors. NRI quantifies&#x0201d;the correctness of upward and downward reclassification or movement of predicted probabilities as a result of adding a new marker&#x0201d;. The confidence interval for NRI was calculated using the percentiles of 1000 bootstrap replications.</p><p>We also performed a sensitivity analysis using the multiple-imputation technique
[<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B18">18</xref>] (with 10 replications) for missing QoL data. The choice of 10 replications was prompted by the large amount of missing QoL data in the trial (60%). In line with Van Buuren&#x02019;s method
[<xref ref-type="bibr" rid="B19">19</xref>], the demographic and clinical variables initially included in the final complete-data model, those associated with the lack of QoL data and those strongly associated with OS (albeit absent from the final model) were used as predictors for the imputation of missing QoL data using a logistic regression model (QoL coded as 2&#x02013;3 vs. 1). Multiple imputation with 10 replications (of the original database) consisted in creating 10 plausible values for each missing data and thus generating 10 new complete databases. For each of the new databases, a standard analysis was performed and the results were combined into a single estimation of the parameter of interest, while taking account of the uncertainty of the imputation technique
[<xref ref-type="bibr" rid="B20">20</xref>]. Variables selected more than 5 times out of 10 replications were included in the multivariate model after multiple imputations.</p><p>Since there was no within-imputation variance according to the Schemper statistic, the pooled estimate was presented as the median [range]
[<xref ref-type="bibr" rid="B20">20</xref>].</p><p>Construction of the a modified prognostic index was based on linear transformation as follows: The regression coefficient for each variable selected in the final multivariate complete case Cox model was divided by the lowest coefficient and rounded to the nearest integer
[<xref ref-type="bibr" rid="B21">21</xref>]. The sum of these integers is the maximum score (M) for the modified index; hence the new score varied from zero to M. According to the score, the modified prognostic index was then arbitrary divided into three risk groups: good prognostic, intermediate prognostic and poor prognostic.</p><p>Survival distributions were estimated using the Kaplan-Meier method
[<xref ref-type="bibr" rid="B22">22</xref>] and compared with the log-rank test.</p><p>All statistical analyses were carried out using SAS&#x000ae; software (version 9.2, SAS Institute Inc., Cary, NC) and R.2.12.0 software (free) using the Design, SurvIDINRI (for NRIs) and Multivariate Imputation by Chained Equations packages (
<ext-link ext-link-type="uri" xlink:href="http://www.multiple-imputation.com/">http://www.multiple-imputation.com/</ext-link>). P-values were two-sided and variables with p&#x0003c;0.05 were considered significantly associated with OS in multivariate models.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Patient characteristics</title><p>The patient baseline characteristics are summarized in Table&#x000a0;
<xref ref-type="table" rid="T1">1</xref>, most of them were male (59%) and 43% were over the age of 65. Synchronous metastasis was predominant (68%) and most of the patients with metachronous metastasis received adjuvant chemotherapy (66%, 130/196).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Baseline demographic, clinical and laboratory variables for patients with and without available QoL data</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="top"><tr><th align="left">&#x000a0;</th><th align="left">&#x000a0;</th><th colspan="2" align="center"><bold>All patients</bold></th><th colspan="2" align="center"><bold>Available QoL</bold></th><th colspan="2" align="center"><bold>Missing QoL</bold></th><th align="center"><bold>All patients</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom"><bold>Variable</bold><hr/></td><td align="left" valign="bottom">Class<hr/></td><td align="center" valign="bottom">N<hr/></td><td align="center" valign="bottom">%<hr/></td><td align="center" valign="bottom">N<hr/></td><td align="center" valign="bottom">%<hr/></td><td align="center" valign="bottom">N<hr/></td><td align="center" valign="bottom">%<hr/></td><td align="center" valign="bottom">P<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Age</bold><hr/></td><td align="left" valign="bottom">&#x02264;65<hr/></td><td align="center" valign="bottom">353<hr/></td><td align="center" valign="bottom">57<hr/></td><td align="center" valign="bottom">138<hr/></td><td align="center" valign="bottom">55<hr/></td><td align="center" valign="bottom">215<hr/></td><td align="center" valign="bottom">58<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x0003e;65<hr/></td><td align="center" valign="bottom">267<hr/></td><td align="center" valign="bottom">43<hr/></td><td align="center" valign="bottom">111<hr/></td><td align="center" valign="bottom">45<hr/></td><td align="center" valign="bottom">156<hr/></td><td align="center" valign="bottom">42<hr/></td><td align="center" valign="bottom">0.2900<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Gender</bold><hr/></td><td align="left" valign="bottom">Male<hr/></td><td align="center" valign="bottom">367<hr/></td><td align="center" valign="bottom">59<hr/></td><td align="center" valign="bottom">151<hr/></td><td align="center" valign="bottom">61<hr/></td><td align="center" valign="bottom">216<hr/></td><td align="center" valign="bottom">58<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">Female<hr/></td><td align="center" valign="bottom">252<hr/></td><td align="center" valign="bottom">41<hr/></td><td align="center" valign="bottom">98<hr/></td><td align="center" valign="bottom">39<hr/></td><td align="center" valign="bottom">154<hr/></td><td align="center" valign="bottom">42<hr/></td><td align="center" valign="bottom">0.5739<hr/></td></tr><tr><td align="left" valign="bottom"><bold>PS</bold><hr/></td><td align="left" valign="bottom">0<hr/></td><td align="center" valign="bottom">333<hr/></td><td align="center" valign="bottom">54<hr/></td><td align="center" valign="bottom">122<hr/></td><td align="center" valign="bottom">49<hr/></td><td align="center" valign="bottom">211<hr/></td><td align="center" valign="bottom">57<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">1<hr/></td><td align="center" valign="bottom">239<hr/></td><td align="center" valign="bottom">38<hr/></td><td align="center" valign="bottom">110<hr/></td><td align="center" valign="bottom">44<hr/></td><td align="center" valign="bottom">129<hr/></td><td align="center" valign="bottom">35<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">2<hr/></td><td align="center" valign="bottom">48<hr/></td><td align="center" valign="bottom">8<hr/></td><td align="center" valign="bottom">17<hr/></td><td align="center" valign="bottom">7<hr/></td><td align="center" valign="bottom">31<hr/></td><td align="center" valign="bottom">8<hr/></td><td align="center" valign="bottom">0.0611<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Number of sites</bold><hr/></td><td align="left" valign="bottom">1<hr/></td><td align="center" valign="bottom">354<hr/></td><td align="center" valign="bottom">58<hr/></td><td align="center" valign="bottom">147<hr/></td><td align="center" valign="bottom">59<hr/></td><td align="center" valign="bottom">207<hr/></td><td align="center" valign="bottom">57<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x0003e;1<hr/></td><td align="center" valign="bottom">260<hr/></td><td align="center" valign="bottom">42<hr/></td><td align="center" valign="bottom">102<hr/></td><td align="center" valign="bottom">41<hr/></td><td align="center" valign="bottom">158<hr/></td><td align="center" valign="bottom">43<hr/></td><td align="center" valign="bottom">0.5672<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Liver involvement</bold><hr/></td><td align="left" valign="bottom">No<hr/></td><td align="center" valign="bottom">149<hr/></td><td align="center" valign="bottom">24<hr/></td><td align="center" valign="bottom">52<hr/></td><td align="center" valign="bottom">21<hr/></td><td align="center" valign="bottom">97<hr/></td><td align="center" valign="bottom">27<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">Yes<hr/></td><td align="center" valign="bottom">460<hr/></td><td align="center" valign="bottom">76<hr/></td><td align="center" valign="bottom">197<hr/></td><td align="center" valign="bottom">79<hr/></td><td align="center" valign="bottom">263<hr/></td><td align="center" valign="bottom">73<hr/></td><td align="center" valign="bottom">0.0872<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Metastases</bold><hr/></td><td align="left" valign="bottom">Synchronous<hr/></td><td align="center" valign="bottom">415<hr/></td><td align="center" valign="bottom">68<hr/></td><td align="center" valign="bottom">168<hr/></td><td align="center" valign="bottom">68<hr/></td><td align="center" valign="bottom">247<hr/></td><td align="center" valign="bottom">68<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">Metachronous<hr/></td><td align="center" valign="bottom">196<hr/></td><td align="center" valign="bottom">32<hr/></td><td align="center" valign="bottom">80<hr/></td><td align="center" valign="bottom">32<hr/></td><td align="center" valign="bottom">116<hr/></td><td align="center" valign="bottom">32<hr/></td><td align="center" valign="bottom">0.9374<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Adjuvant chemotherapy</bold><hr/></td><td align="left" valign="bottom">No<hr/></td><td align="center" valign="bottom">488<hr/></td><td align="center" valign="bottom">79<hr/></td><td align="center" valign="bottom">200<hr/></td><td align="center" valign="bottom">81<hr/></td><td align="center" valign="bottom">288<hr/></td><td align="center" valign="bottom">78<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">Yes<hr/></td><td align="center" valign="bottom">130<hr/></td><td align="center" valign="bottom">21<hr/></td><td align="center" valign="bottom">48<hr/></td><td align="center" valign="bottom">19<hr/></td><td align="center" valign="bottom">82<hr/></td><td align="center" valign="bottom">22<hr/></td><td align="center" valign="bottom">0.4013<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Tumour site</bold><hr/></td><td align="left" valign="bottom">Colon<hr/></td><td align="center" valign="bottom">398<hr/></td><td align="center" valign="bottom">64<hr/></td><td align="center" valign="bottom">160<hr/></td><td align="center" valign="bottom">64<hr/></td><td align="center" valign="bottom">238<hr/></td><td align="center" valign="bottom">64<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">Rectum<hr/></td><td align="center" valign="bottom">211<hr/></td><td align="center" valign="bottom">34<hr/></td><td align="center" valign="bottom">86<hr/></td><td align="center" valign="bottom">35<hr/></td><td align="center" valign="bottom">125<hr/></td><td align="center" valign="bottom">35<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">both<hr/></td><td align="center" valign="bottom">11<hr/></td><td align="center" valign="bottom">2<hr/></td><td align="center" valign="bottom">3<hr/></td><td align="center" valign="bottom">1<hr/></td><td align="center" valign="bottom">8<hr/></td><td align="center" valign="bottom">1<hr/></td><td align="center" valign="bottom">0.6730<hr/></td></tr><tr><td align="left" valign="bottom"><bold>LDH</bold><hr/></td><td align="left" valign="bottom">&#x02264;1xULN<hr/></td><td align="center" valign="bottom">380<hr/></td><td align="center" valign="bottom">61<hr/></td><td align="center" valign="bottom">134<hr/></td><td align="center" valign="bottom">56<hr/></td><td align="center" valign="bottom">246<hr/></td><td align="center" valign="bottom">66<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x0003e;1xULN<hr/></td><td align="center" valign="bottom">240<hr/></td><td align="center" valign="bottom">39<hr/></td><td align="center" valign="bottom">115<hr/></td><td align="center" valign="bottom">44<hr/></td><td align="center" valign="bottom">125<hr/></td><td align="center" valign="bottom">34<hr/></td><td align="center" valign="bottom">0.0017<hr/></td></tr><tr><td align="left" valign="bottom"><bold>ALP</bold><hr/></td><td align="left" valign="bottom">&#x02264;1xULN<hr/></td><td align="center" valign="bottom">350<hr/></td><td align="center" valign="bottom">56<hr/></td><td align="center" valign="bottom">129<hr/></td><td align="center" valign="bottom">52<hr/></td><td align="center" valign="bottom">221<hr/></td><td align="center" valign="bottom">60<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x0003e;1xULN<hr/></td><td align="center" valign="bottom">270<hr/></td><td align="center" valign="bottom">44<hr/></td><td align="center" valign="bottom">120<hr/></td><td align="center" valign="bottom">48<hr/></td><td align="center" valign="bottom">150<hr/></td><td align="center" valign="bottom">40<hr/></td><td align="center" valign="bottom">0.0560<hr/></td></tr><tr><td align="left" valign="bottom"><bold>CEA</bold><hr/></td><td align="left" valign="bottom">&#x02264;1xULN<hr/></td><td align="center" valign="bottom">177<hr/></td><td align="center" valign="bottom">28<hr/></td><td align="center" valign="bottom">61<hr/></td><td align="center" valign="bottom">25<hr/></td><td align="center" valign="bottom">116<hr/></td><td align="center" valign="bottom">31<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x0003e;1xULN<hr/></td><td align="center" valign="bottom">443<hr/></td><td align="center" valign="bottom">72<hr/></td><td align="center" valign="bottom">188<hr/></td><td align="center" valign="bottom">75<hr/></td><td align="center" valign="bottom">255<hr/></td><td align="center" valign="bottom">69<hr/></td><td align="center" valign="bottom">0.0673<hr/></td></tr><tr><td align="left" valign="bottom"><bold>EuroQoL</bold><hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Mobility</bold><hr/></td><td align="left" valign="bottom">1<hr/></td><td align="center" valign="bottom">223<hr/></td><td align="center" valign="bottom">81<hr/></td><td align="center" valign="bottom">223<hr/></td><td align="center" valign="bottom">81<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">2-3<hr/></td><td align="center" valign="bottom">54<hr/></td><td align="center" valign="bottom">19<hr/></td><td align="center" valign="bottom">54<hr/></td><td align="center" valign="bottom">19<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Self-care</bold><hr/></td><td align="left" valign="bottom">1<hr/></td><td align="center" valign="bottom">255<hr/></td><td align="center" valign="bottom">93<hr/></td><td align="center" valign="bottom">255<hr/></td><td align="center" valign="bottom">93<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">2-3<hr/></td><td align="center" valign="bottom">19<hr/></td><td align="center" valign="bottom">7<hr/></td><td align="center" valign="bottom">19<hr/></td><td align="center" valign="bottom">7<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Usual activities</bold><hr/></td><td align="left" valign="bottom">1<hr/></td><td align="center" valign="bottom">193<hr/></td><td align="center" valign="bottom">71<hr/></td><td align="center" valign="bottom">193<hr/></td><td align="center" valign="bottom">71<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">2-3<hr/></td><td align="center" valign="bottom">79<hr/></td><td align="center" valign="bottom">29<hr/></td><td align="center" valign="bottom">79<hr/></td><td align="center" valign="bottom">29<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Pain/discomfort</bold><hr/></td><td align="left" valign="bottom">1<hr/></td><td align="center" valign="bottom">137<hr/></td><td align="center" valign="bottom">50<hr/></td><td align="center" valign="bottom">137<hr/></td><td align="center" valign="bottom">50<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">2-3<hr/></td><td align="center" valign="bottom">138<hr/></td><td align="center" valign="bottom">50<hr/></td><td align="center" valign="bottom">138<hr/></td><td align="center" valign="bottom">50<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Anxiety/depression</bold><hr/></td><td align="left" valign="bottom">1<hr/></td><td align="center" valign="bottom">145<hr/></td><td align="center" valign="bottom">53<hr/></td><td align="center" valign="bottom">145<hr/></td><td align="center" valign="bottom">53<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">2-3<hr/></td><td align="center" valign="bottom">130<hr/></td><td align="center" valign="bottom">47<hr/></td><td align="center" valign="bottom">130<hr/></td><td align="center" valign="bottom">47<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left"><bold>VAS score</bold></td><td align="left">&#x000a0;</td><td colspan="2" align="center">&#x000a0;</td><td colspan="2" align="center">70 [10&#x02013;100] <sup>**</sup></td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td></tr></tbody></table><table-wrap-foot><p><sup>**</sup> Median (range).</p><p>ULN= Upper Limit of Normal.</p><p>VAS= visual analogue scale.</p><p>PS= performance status.</p><p>ALP= alkaline phosphatase.</p><p>LDH= serum lactate dehydrogenase.</p></table-wrap-foot></table-wrap><p>Data on QoL was available for 249 of the 620 patients in the original OPTIMOX1 cohort (40%). Normal serum LDH was significantly more frequent in patients with missing QoL data. Patients with missing QoL data also tended to have lower serum ALP levels, a better PS and less liver involvement compared to patients with available QoL. Of the 249 patients, 75% died after a median follow-up period of 35.8 months (95% CI = [33.8&#x02013;38.4]). There was no apparent correlation between the availability of QoL datasets and OS (Log-rank pvalue = 0.62; Figure&#x000a0;
<xref ref-type="fig" rid="F1">1</xref>).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Overall survival (in months) of patients lacking QoL data (dotted line; n = 371) and patients with available QoL data (solid line; n = 249).</bold> Log-rank p value = 0.62. The median survival times for patient with and without QoL datasets were 18.6 months (95% CI [17.0 - 21.6]) and 20.8 months (95% CI = [19.5&#x02013;22.2]), respectively.</p></caption><graphic xlink:href="1477-7525-12-69-1"/></fig><p>Most of the patients had good QoL: 81%, 93%, 71%, 50% and 53% had no problems in terms of mobility, self-care, usual activities, pain/discomfort and anxiety/depression, respectively. The median VAS score was 70 (range = [10&#x02013;100]).</p></sec><sec><title>Univariate analysis</title><p>Given that&#x0201d;extreme problems&#x0201d; (coded as 3) were infrequent, QoL item scores were pooled into two classes (i.e. a score of 1 vs. a score of 2 or 3). We also combined PS into 2 classes (0 vs. 1&#x02013;2), due to the low proportion of patients with a PS score of 2.</p><p>Univariate analyses of clinical and QoL variables are summarized in Table&#x000a0;
<xref ref-type="table" rid="T2">2</xref>. High serum LDH, poor PS, high serum ALP, &#x0003e;1 metastatic sites, age&#x0003e;65, high serum CEA, mobility problems (as coded 2&#x02013;3) (Figure&#x000a0;
<xref ref-type="fig" rid="F2">2</xref>), pain/discomfort problems (as coded 2&#x02013;3) and anxiety/depression problems (as coded 2&#x02013;3) were associated with a poorer prognosis.</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Univariate and multivariate Cox analyses</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="top"><tr><th rowspan="2" align="left">&#x000a0;</th><th rowspan="2" align="left">&#x000a0;</th><th rowspan="2" colspan="3" align="center"><bold>Univariate analysis</bold></th><th colspan="3" align="center" valign="bottom"><bold>Multivariate analysis</bold><hr/></th><th colspan="3" align="center" valign="bottom"><bold>Multivariate analysis</bold><hr/></th></tr><tr><th colspan="3" align="center"><bold>Model not including QoL</bold></th><th colspan="3" align="center"><bold>Full model, including QoL</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom"><bold>Variable</bold><hr/></td><td align="left" valign="bottom">Class<hr/></td><td align="center" valign="bottom">HR<hr/></td><td align="center" valign="bottom">95% CI<hr/></td><td align="center" valign="bottom">P<hr/></td><td align="center" valign="bottom">HR<hr/></td><td align="center" valign="bottom">95% CI<hr/></td><td align="center" valign="bottom">P<hr/></td><td align="center" valign="bottom">HR<hr/></td><td align="center" valign="bottom">95% CI<hr/></td><td align="center" valign="bottom">P<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Age</bold><hr/></td><td align="left" valign="bottom">&#x02264;65<hr/></td><td align="center" valign="bottom">1<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x0003e;65<hr/></td><td align="center" valign="bottom">1.42<hr/></td><td align="center" valign="bottom">1.06 &#x02013; 1.89<hr/></td><td align="center" valign="bottom">0.0178<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Gender</bold><hr/></td><td align="left" valign="bottom">Male<hr/></td><td align="center" valign="bottom">1<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">Female<hr/></td><td align="center" valign="bottom">1.06<hr/></td><td align="center" valign="bottom">0.79 &#x02013; 1.42<hr/></td><td align="center" valign="bottom">0.6945<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><bold>PS</bold><hr/></td><td align="left" valign="bottom">0<hr/></td><td align="center" valign="bottom">1<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">1<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">1<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">1-2<hr/></td><td align="center" valign="bottom">1.84<hr/></td><td align="center" valign="bottom">1.38 &#x02013; 2.46<hr/></td><td align="center" valign="bottom">&#x0003c;0.0001<hr/></td><td align="center" valign="bottom">1.98<hr/></td><td align="center" valign="bottom">1.44 &#x02013; 2.73<hr/></td><td align="center" valign="bottom">&#x0003c;0.0001<hr/></td><td align="center" valign="bottom">1.87<hr/></td><td align="center" valign="bottom">1.35 &#x02013; 2.59<hr/></td><td align="center" valign="bottom">0.0002<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Number of sites</bold><hr/></td><td align="left" valign="bottom">1<hr/></td><td align="center" valign="bottom">1<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">1<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">1<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x0003e;1<hr/></td><td align="center" valign="bottom">1.47<hr/></td><td align="center" valign="bottom">1.10 &#x02013; 1.97<hr/></td><td align="center" valign="bottom">0.0094<hr/></td><td align="center" valign="bottom">1.48<hr/></td><td align="center" valign="bottom">1.08 &#x02013; 2.05<hr/></td><td align="center" valign="bottom">0.0160<hr/></td><td align="center" valign="bottom">1.48<hr/></td><td align="center" valign="bottom">1.07 &#x02013; 2.04<hr/></td><td align="center" valign="bottom">0.0176<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Liver involvement</bold><hr/></td><td align="left" valign="bottom">No<hr/></td><td align="center" valign="bottom">1<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">Yes<hr/></td><td align="center" valign="bottom">1.14<hr/></td><td align="center" valign="bottom">0.795 &#x02013; 1.65<hr/></td><td align="center" valign="bottom">0.4699<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Metastases</bold><hr/></td><td align="left" valign="bottom">Synchronous<hr/></td><td align="center" valign="bottom">1<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">Metachronous<hr/></td><td align="center" valign="bottom">0.89<hr/></td><td align="center" valign="bottom">0.61 &#x02013; 1.29<hr/></td><td align="center" valign="bottom">0.5403<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Adjuvant chemotherapy</bold><hr/></td><td align="left" valign="bottom">No<hr/></td><td align="center" valign="bottom">1<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">Yes<hr/></td><td align="center" valign="bottom">0.95<hr/></td><td align="center" valign="bottom">0.76 &#x02013; 1.19<hr/></td><td align="center" valign="bottom">0.68<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><bold>LDH</bold><hr/></td><td align="left" valign="bottom">&#x02264;1xULN<hr/></td><td align="center" valign="bottom">1<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">1<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">1<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x0003e;1xULN<hr/></td><td align="center" valign="bottom">2.04<hr/></td><td align="center" valign="bottom">1.48 &#x02013; 2.80<hr/></td><td align="center" valign="bottom">&#x0003c;0.0001<hr/></td><td align="center" valign="bottom">1.93<hr/></td><td align="center" valign="bottom">1.39 &#x02013; 2.68<hr/></td><td align="center" valign="bottom">&#x0003c;0.0001<hr/></td><td align="center" valign="bottom">1.83<hr/></td><td align="center" valign="bottom">1.31 &#x02013; 2.55<hr/></td><td align="center" valign="bottom">0.0004<hr/></td></tr><tr><td align="left" valign="bottom"><bold>APL</bold><hr/></td><td align="left" valign="bottom">&#x02264;1xULN<hr/></td><td align="center" valign="bottom">1<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x0003e;1xULN<hr/></td><td align="center" valign="bottom">1.60<hr/></td><td align="center" valign="bottom">1.20 &#x02013; 2.14<hr/></td><td align="center" valign="bottom">0.0016<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><bold>CEA</bold><hr/></td><td align="left" valign="bottom">&#x02264;1xULN<hr/></td><td align="center" valign="bottom">1<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x0003e;1xULN<hr/></td><td align="center" valign="bottom">1.48<hr/></td><td align="center" valign="bottom">1.01 &#x02013; 2.18<hr/></td><td align="center" valign="bottom">0.0444<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><bold>EuroQoL</bold><hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Mobility</bold><hr/></td><td align="left" valign="bottom">1<hr/></td><td align="center" valign="bottom">1<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">1<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">2-3<hr/></td><td align="center" valign="bottom">1.90<hr/></td><td align="center" valign="bottom">1.33 &#x02013; 2.71<hr/></td><td align="center" valign="bottom">0.0004<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">1.66<hr/></td><td align="center" valign="bottom">1.12 &#x02013; 2.48<hr/></td><td align="center" valign="bottom">0.0117<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Self-care</bold><hr/></td><td align="left" valign="bottom">1<hr/></td><td align="center" valign="bottom">1<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">2-3<hr/></td><td align="center" valign="bottom">1.52<hr/></td><td align="center" valign="bottom">0.88 &#x02013; 2.62<hr/></td><td align="center" valign="bottom">0.1322<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Usual activities</bold><hr/></td><td align="left" valign="bottom">1<hr/></td><td align="center" valign="bottom">1<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">2-3<hr/></td><td align="center" valign="bottom">1.20<hr/></td><td align="center" valign="bottom">0.88 &#x02013; 1.64<hr/></td><td align="center" valign="bottom">0.2553<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Pain/discomfort</bold><hr/></td><td align="left" valign="bottom">1<hr/></td><td align="center" valign="bottom">1<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">2-3<hr/></td><td align="center" valign="bottom">1.39<hr/></td><td align="center" valign="bottom">1.04 &#x02013; 1.86<hr/></td><td align="center" valign="bottom">0.0239<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Anxiety/depression</bold><hr/></td><td align="left" valign="bottom">1<hr/></td><td align="center" valign="bottom">1<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">2-3<hr/></td><td align="center" valign="bottom">1.45<hr/></td><td align="center" valign="bottom">1.09 &#x02013; 1.93<hr/></td><td align="center" valign="bottom">0.0116<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><bold>VAS score</bold><hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">1.001<hr/></td><td align="center" valign="bottom">0.996 &#x02013; 1.005<hr/></td><td align="center" valign="bottom">0.7975<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td rowspan="2" colspan="2" align="left" valign="bottom"><bold>Harrell&#x02019;s C index</bold><hr/></td><td rowspan="2" align="center" valign="bottom">&#x000a0;<hr/></td><td rowspan="2" align="center" valign="bottom">&#x000a0;<hr/></td><td rowspan="2" align="center" valign="bottom">&#x000a0;<hr/></td><td rowspan="2" align="center" valign="bottom">&#x000a0;<hr/></td><td colspan="2" align="center" valign="bottom">0.65 [0.61 &#x02013; 0.69]<hr/></td><td rowspan="2" align="center" valign="bottom">&#x000a0;<hr/></td><td colspan="2" align="center" valign="bottom">0.67 [0.63 &#x02013; 0.71]<hr/></td></tr><tr><td colspan="2" align="center" valign="bottom">0.65*<hr/></td><td colspan="2" align="center" valign="bottom">0.66*<hr/></td></tr><tr><td colspan="2" align="left"><bold>Schemper statistic</bold></td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td><td colspan="2" align="center">9.32%</td><td align="center">&#x000a0;</td><td colspan="2" align="center">10.42%</td></tr></tbody></table><table-wrap-foot><p>ULN = Upper Limit of Normal.</p><p>* = Optimism-corrected C-index.</p></table-wrap-foot></table-wrap><fig id="F2" position="float"><label>Figure 2</label><caption><p><bold>Overall survival (in months) of patients with mobility problems (as coded 2&#x02013;3) (dotted line; n = 54) and patients without mobility problems (as coded 1) (solid line; n = 223). Log-rank p value = 0.0011.</bold> The median survival times were 20.9 (95% CI = [18.6&#x02013;24.9]) months and 11.8 (95% CI = [11.1&#x02013;17.3]) months for patients without problems (coded as 1) and those with problems (as coded 2&#x02013;3), respectively.</p></caption><graphic xlink:href="1477-7525-12-69-2"/></fig><p>There were no significant associations between the risk of death and self-care (p = 0.1322), usual activities (p = 0.2553) and the VAS score (p = 0.1280) QoL scales on the other.</p></sec><sec><title>Multivariate analysis</title><p>The results for multivariate analyses are summarized on Table&#x000a0;
<xref ref-type="table" rid="T2">2</xref>.</p><p>In the first model, high LDH, &#x0003e;1 metastatic sites and poor PS were associated with a shorter survival.</p><p>In the second model, high LDH, &#x0003e;1 metastatic sites, poor PS and mobility problems were associated with a shorter survival.</p><p>After multiple imputations, the pooled HR for mobility was 1.57 (95% CI = [1.16&#x02013;2.12]) (p = 0.0043) in the model including LDH, the number of metastatic sites, PS, ALP, pain/discomfort and mobility (Additional file
<xref ref-type="supplementary-material" rid="S1">1</xref>).</p></sec><sec><title>Improvement of prognostic indices</title><p>In order to evaluate improvements in performance of the K&#x000f6;hne and GERCOR prognostic indices, we first calculated their performance in our population (Table&#x000a0;
<xref ref-type="table" rid="T3">3</xref>).</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Improvement of K&#x000f6;hne prognostic index</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="center"/><col align="center"/><col align="center"/><col align="left"/><col align="left"/><col align="center"/></colgroup><thead valign="top"><tr><th colspan="6" align="center"><bold>K&#x000f6;hne prognostic index</bold></th></tr></thead><tbody valign="top"><tr><td align="center" valign="bottom">Variable<hr/></td><td align="center" valign="bottom">HR (95% CI)<hr/></td><td align="center" valign="bottom">P value<hr/></td><td align="left" valign="bottom">c-index<hr/></td><td align="left" valign="bottom">Schemper (%)<hr/></td><td align="center" valign="bottom">NRI (95% CI)<hr/></td></tr><tr><td align="center" valign="bottom">K&#x000f6;hne (2 vs. 1)<hr/></td><td align="center" valign="bottom">1.18 [0.96 &#x02013; 1.47]<hr/></td><td align="center" valign="bottom">=0.1200<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="center" valign="bottom">K&#x000f6;hne (3 vs. 1)<hr/></td><td align="center" valign="bottom">2.66 [1.84 &#x02013; 3.85]<hr/></td><td align="center" valign="bottom">&#x0003c;0.0001<hr/></td><td align="left" valign="bottom">0.54 [0.51 -0.57] *0.54<hr/></td><td align="left" valign="bottom">1.6<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td colspan="6" align="center" valign="bottom"><bold>Improvement of the K&#x000f6;hne prognostic index with clinical and QoL factors: complete-case analysis</bold><hr/></td></tr><tr><td align="center" valign="bottom">&#x02003;&#x02003;&#x02003;K&#x000f6;hne (2 vs. 1)<hr/></td><td align="center" valign="bottom">1.11 [0.80 &#x02013; 1.55]<hr/></td><td align="center" valign="bottom">=0.5114<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">NRI at 12 months = 0.23 ([0.07; 0.46])<hr/></td></tr><tr><td colspan="5" align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">NRI at 24 months = 0.31 ([0.16; 0.44])<hr/></td></tr><tr><td align="center" valign="bottom">K&#x000f6;hne (3 vs. 1)<hr/></td><td align="center" valign="bottom">2.17 [1.25 &#x02013; 3.75]<hr/></td><td align="center" valign="bottom">=0.0056<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td colspan="5" align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">NRI at 36 months = 0.27 ([0.02; 0.50])<hr/></td></tr><tr><td align="center" valign="bottom">LDH (&#x0003e;1ULN vs. &#x02264; 1ULN)<hr/></td><td align="center" valign="bottom">2.09 [1.53 &#x02013; 2.87]<hr/></td><td align="center" valign="bottom">&#x0003c;0.0001<hr/></td><td align="left" valign="bottom">0.67 [0.63 -0.71]<hr/></td><td align="left" valign="bottom">10.8<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="center" valign="bottom">Mobility (2&#x02013;3 vs. 1)<hr/></td><td align="center" valign="bottom">1.56 [1.05 &#x02013; 2.32]<hr/></td><td align="center" valign="bottom">=0.0266<hr/></td><td align="left" valign="bottom">*0.66<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="center" valign="bottom">Pain/discomfort (2&#x02013;3 vs. 1)<hr/></td><td align="center" valign="bottom">1.60 [1.17 &#x02013; 2.18]<hr/></td><td align="center" valign="bottom">=0.0031<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td colspan="6" align="center" valign="bottom"><bold>Improvement of the K&#x000f6;hne prognostic index with clinical and QoL factors after multiple imputation</bold><hr/></td></tr><tr><td align="center" valign="bottom">K&#x000f6;hne (2 vs. 1)<hr/></td><td align="center" valign="bottom">1.24 [0.97 &#x02013; 1.58]<hr/></td><td align="center" valign="bottom">=0.0780<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="center" valign="bottom">K&#x000f6;hne (3 vs. 1)<hr/></td><td align="center" valign="bottom">2.15 [1.43 &#x02013; 3.24]<hr/></td><td align="center" valign="bottom">=0.0002<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="center" valign="bottom">LDH (&#x0003e;1ULN vs. &#x02264; 1ULN)<hr/></td><td align="center" valign="bottom">1.99 [1.61 &#x02013; 2.46]<hr/></td><td align="center" valign="bottom">&#x0003c;0.0001<hr/></td><td align="left" valign="bottom">0.66 [0.59 -0.73]<hr/></td><td align="left" valign="bottom">8.63 [7.74 &#x02013; 10.8]<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="center" valign="bottom">Mobility (2&#x02013;3 vs. 1)<hr/></td><td align="center" valign="bottom">1.39 [1.06 &#x02013; 1.83]<hr/></td><td align="center" valign="bottom">=0.0191<hr/></td><td align="left" valign="bottom">R = 65%<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="center">Pain/discomfort (2&#x02013;3 vs. 1)</td><td align="center">1.67 [1.20 &#x02013; 2.31]</td><td align="center">=0.0031</td><td align="left">R = 113%</td><td align="left">&#x000a0;</td><td align="center">&#x000a0;</td></tr></tbody></table><table-wrap-foot><p>LDH = lactate dehydrogenase.</p><p>ULN = Upper Limit of Normal.</p><p>* = bootstrap C-index.</p><p>R = relative increase in variance due to missing data.</p><p>QoL = Quality of Life.</p><p>HR = Hazard ratio.</p><p>NRI = net reclassification improvement.</p><p>For multiple imputations, a logistic model was used: response variable = QoL scale (2&#x02013;3 vs. 1) and exploratory variables were number of metastatic sites, liver involvement, WHO Performance Status, CEA, APL and LDH.</p><p>Variables considered in the imputation method (last model) were selected more than 5 times among the 10 replications of multiple imputations (see statistical method).</p></table-wrap-foot></table-wrap><sec><title>Improvement of the K&#x000f6;hne prognostic index</title><p>After addition of QoL and clinical variables to the K&#x000f6;hne prognostic index in a complete-case analysis (N = 236), high LDH, mobility and pain/discomfort problems appeared to be related to a shorter survival (Table&#x000a0;
<xref ref-type="table" rid="T4">4</xref>). The C-index and Schemper statistic were improved while the NRIs were significantly different from zero (Table&#x000a0;
<xref ref-type="table" rid="T3">3</xref>). A modified K&#x000f6;hne prognostic index was built using the above variables (Table&#x000a0;
<xref ref-type="table" rid="T5">5</xref>).</p><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Improvement of the GERCOR prognostic index</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="left"/></colgroup><thead valign="top"><tr><th colspan="6" align="center"><bold>GERCOR prognostic index</bold></th></tr></thead><tbody valign="top"><tr><td align="center" valign="bottom">Variable<hr/></td><td align="center" valign="bottom">HR (95% CI)<hr/></td><td align="center" valign="bottom">P value<hr/></td><td align="center" valign="bottom">c-index<hr/></td><td align="center" valign="bottom">Schemper (%)<hr/></td><td align="left" valign="bottom">NRI (95% CI)<hr/></td></tr><tr><td align="center" valign="bottom">GERCOR (2 vs. 1)<hr/></td><td align="center" valign="bottom">1.82 [1.43 &#x02013; 2.33]<hr/></td><td align="center" valign="bottom">&#x0003c;0.0001<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="center" valign="bottom">&#x02003;&#x02003;&#x02003;&#x000a0;GERCOR (3 vs. 1)<hr/></td><td align="center" valign="bottom">3.10 [2.38 &#x02013; 4.05]<hr/></td><td align="center" valign="bottom">&#x0003c;0.0001<hr/></td><td align="center" valign="bottom">0.63 [0.61 -0.66] *0.63<hr/></td><td align="center" valign="bottom">6.44<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td colspan="6" align="center" valign="bottom"><bold>Improvement of the GERCOR prognostic index clinical and QoL factors: complete-case analysis</bold><hr/></td></tr><tr><td align="center" valign="bottom">GERCOR (2 vs. 1)<hr/></td><td align="center" valign="bottom">1.70 [1.14 &#x02013; 2.54]<hr/></td><td align="center" valign="bottom">=0.0090<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">NRI at 12 months = 0.35 [0.06; 0.44]<hr/></td></tr><tr><td align="center" valign="bottom">GERCOR (3 vs. 1)<hr/></td><td align="center" valign="bottom">3.35 [2.20 &#x02013; 5.10]<hr/></td><td align="center" valign="bottom">&#x0003c;0.0001<hr/></td><td align="center" valign="bottom">0.67 [0.63 -0.71] *0.67<hr/></td><td align="center" valign="bottom">11.52<hr/></td><td align="left" valign="bottom">NRI at 24 months = 0.27 [0.04; 0.38]<hr/></td></tr><tr><td colspan="5" align="center" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">NRI at 36 months = 0.28 [0.01; 0.45]<hr/></td></tr><tr><td align="center" valign="bottom">Mobility (2&#x02013;3 vs. 1)<hr/></td><td align="center" valign="bottom">1.77 [1.19 &#x02013; 2.62]<hr/></td><td align="center" valign="bottom">=0.0047<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="center" valign="bottom">Anxiety/depression (2&#x02013;3 vs. 1)<hr/></td><td align="center" valign="bottom">1.41 [1.03 &#x02013; 1.92]<hr/></td><td align="center" valign="bottom">=0.0314<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td colspan="6" align="center" valign="bottom"><bold>Improvement of the GERCOR prognostic index clinical and QoL factors: multiple imputation</bold><hr/></td></tr><tr><td align="center" valign="bottom">GERCOR (2 vs. 1)<hr/></td><td align="center" valign="bottom">1.77 [1.36 &#x02013; 2.30]<hr/></td><td align="center" valign="bottom">&#x0003c;0.0001<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="center" valign="bottom">GERCOR (3 vs. 1)<hr/></td><td align="center" valign="bottom">2.49 [1.84 &#x02013; 3.38]<hr/></td><td align="center" valign="bottom">&#x0003c;0.0001<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="center" valign="bottom">ALP (&#x0003e;1ULN vs. &#x02264; 1ULN)<hr/></td><td align="center" valign="bottom">1.25 [1.00 &#x02013; 1.57]<hr/></td><td align="center" valign="bottom">=0.0480<hr/></td><td align="center" valign="bottom">0.67 [0.64 -0.71]<hr/></td><td align="center" valign="bottom">9.56 [8.76 &#x02013; 11.52]<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="center" valign="bottom">Mobility (2&#x02013;3 vs. 1)<hr/></td><td align="center" valign="bottom">1.42 [1.08 &#x02013; 1.86]<hr/></td><td align="center" valign="bottom">=0.0120<hr/></td><td align="center" valign="bottom">R = 60%<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="center">Pain/discomfort (2&#x02013;3 vs. 1)</td><td align="center">1.55 [1.10 &#x02013; 2.20]</td><td align="center">=0.0140</td><td align="center">R = 138%</td><td align="center">&#x000a0;</td><td align="left">&#x000a0;</td></tr></tbody></table><table-wrap-foot><p>LD = lactate dehydrogenase.</p><p>ULN = Upper Limit of Normal.</p><p>* = bootstrap C-index.</p><p>R = relative increase in variance due to missing data.</p><p>QoL = Quality of Life.</p><p>HR = Hazard ratio.</p><p>NRI = net reclassification improvement.</p><p>For multiple imputations, a logistic model was used: response variable=QoL scale (2&#x02013;3 vs. 1) and exploratory variables were number of metastatic sites, liver involvement, WHO Performance Status, CEA, APL and LDH.</p><p>Variables considered in the imputation method (last model) were selected more than 5 times among the 10 replications of multiple imputations (see statistical method).</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T5"><label>Table 5</label><caption><p>Modified K&#x000f6;hne prognostic index</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="top"><tr><th align="left">&#x000a0;</th><th align="left"><bold>0 point</bold></th><th align="left"><bold>1 point</bold></th><th align="left"><bold>2 points</bold></th><th align="left"><bold>3 points</bold></th><th align="left"><bold>4 points</bold></th><th align="left"><bold>5 points</bold></th><th align="left"><bold>6 points</bold></th><th align="left"><bold>7 points</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom">K&#x000f6;hne<hr/></td><td align="left" valign="bottom">K&#x000f6;hne I<hr/></td><td align="left" valign="bottom">K&#x000f6;hne II<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">K&#x000f6;hne III<hr/></td></tr><tr><td align="left" valign="bottom">LDH<hr/></td><td align="left" valign="bottom">&#x02264; 1ULN<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x0003e;1ULN<hr/></td></tr><tr><td align="left" valign="bottom">Mobility score<hr/></td><td align="left" valign="bottom">1<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">2-3<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left">Pain/discomfort score</td><td align="left">1</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">2-3</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td></tr></tbody></table><table-wrap-foot><p>The modified K&#x000f6;hne index varied from 0 to 22 points.</p><p>Poor prognosis: 15 to 22 points.</p><p>Intermediate prognosis: 8 to 14 points.</p><p>Good prognosis: 0 to 6 points.</p></table-wrap-foot></table-wrap><p>Survival distributions for the K&#x000f6;hne and improved K&#x000f6;hne prognostic systems are shown in Figure&#x000a0;
<xref ref-type="fig" rid="F3">3</xref> A&#x00026;3B.</p><fig id="F3" position="float"><label>Figure 3</label><caption><p><bold>Survival strata according to the K&#x000f6;hne prognostic model before and after improvement. A:</bold> Overall survival (in months) for good, intermediate and poor prognosis according to the K&#x000f6;hne prognostic model. Median survival = 20.7 [17.7 &#x02013; 24.4] for the group with good prognosis (n = 134); Median survival = 18.6 [17.1 &#x02013; 25.4] for the group with intermediate prognosis (n = 84); Median survival = 9.0 [7.3 -14.7] for the group with poor prognosis (n = 18). Log-rank p = 0.0013. Optimism corrected C-index = 0.54. <bold>B:</bold> Overall survival (in months) for good, intermediate and poor prognosis according to the modified K&#x000f6;hne group. Median survival = 27.0 [21.1 &#x02013; 37.5] for the group with good prognosis (n = 57); Median survival = 18.4 [16.5 &#x02013; 21.6] for the group with intermediate prognosis (n = 146); Median survival = 11.3 [9.0 &#x02013; 16.9] for the group with poor prognosis (n = 33). Log-rank p&#x0003c;0.0001. Optimism corrected C-index = 0.60.</p></caption><graphic xlink:href="1477-7525-12-69-3"/></fig><p>The Results of multiple imputations are summarized in Table&#x000a0;
<xref ref-type="table" rid="T3">3</xref>.</p><p>A complete-case analysis of the GERCOR prognostic classification revealed that mobility and Anxiety/depression could improve performance: the C-index, Schemper statistic, and NRI are summarized in Table&#x000a0;
<xref ref-type="table" rid="T4">4</xref>.</p><p>Based on these two new QoL scales, a modified GERCOR prognostic system was built using the above variables (Table&#x000a0;
<xref ref-type="table" rid="T6">6</xref>).</p><table-wrap position="float" id="T6"><label>Table 6</label><caption><p>Modified GERCOR prognostic index</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="top"><tr><th align="left">&#x000a0;</th><th align="left"><bold>0 point</bold></th><th align="left"><bold>1 point</bold></th><th align="left"><bold>2 points</bold></th><th align="left"><bold>3 points</bold></th><th align="left"><bold>4 points</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom">GERCOR<hr/></td><td align="left" valign="bottom">GERCOR I<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">GERCOR II<hr/></td><td align="left" valign="bottom">GERCOR III<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">Mobility score<hr/></td><td align="left" valign="bottom">1<hr/></td><td align="left" valign="bottom">2-3<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left">Pain/discomfort score</td><td align="left">1</td><td align="left">2-3</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td></tr></tbody></table><table-wrap-foot><p>The modified GERCOR index varied from 0 to 5 points.</p><p>Poor prognosis: 4 to 5 points.</p><p>Intermediate prognosis: 2 or 3 points.</p><p>Good prognosis: 0 or 1 point.</p></table-wrap-foot></table-wrap><p>Survival distributions for the GERCOR and improved GERCOR prognostic systems are shown in Figure&#x000a0;
<xref ref-type="fig" rid="F4">4</xref>A and Figure
<xref ref-type="fig" rid="F4">4</xref>B.</p><fig id="F4" position="float"><label>Figure 4</label><caption><p><bold>Survival strata according to the GERCOR prognostic model before and after improvement. A:</bold> Overall survival (in months) for good, intermediate and poor prognosis according to the GERCOR prognostic system. Median survival = 28.7 [24.5 &#x02013; 38.9] for the group with good prognosis (n = 73); Median survival = 19.9 [18.1 &#x02013; 23.9] for the group with intermediate prognosis (n = 97); Median survival = 12.1 [10.0 &#x02013; 15.4] for the group with poor prognosis (n = 66). Log-rank p&#x0003c;0.0001. Optimism corrected C-index = 0.65. <bold>B:</bold> Overall survival (in months) for good, intermediate and poor prognosis according to the modified GERCOR prognostic system. Median survival = 28.2 [24.5 &#x02013; 37.5] for the group with good prognosis (n = 68); Median survival = 21.6 [18.7 &#x02013; 26.2] for the group with intermediate prognosis (n = 90); Median survival = 11.5 [10.0 &#x02013; 14.7] for the group with poor prognosis (n = 78). Log-rank p&#x0003c;0.0001. Optimism corrected C-index = 0.66.</p></caption><graphic xlink:href="1477-7525-12-69-4"/></fig><p>The Results of multiple imputations are summarized in Table&#x000a0;
<xref ref-type="table" rid="T4">4</xref>.</p></sec></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>In this study, EuroQol mobility dimension appeared to be the third most important prognostic factor (measured by the hazard ratio) for overall survival in unresectable mCRC, after serum LDH level and ECOG performance status. Self-reported QoL is known to be associated with OS in several types of cancer
[<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>]. Our present results confirmed the independent prognostic value of QoL scales in patients with mCRC
[<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>]. Our first multivariate model (including clinical and biochemical variables) revealed the prognostic value of LDH, PS and the number of metastatic sites, whereas our second model (with the addition of QoL) confirmed the value of LDH, PS and the number of metastatic sites and further identified the QoL&#x0201d;mobility" scale as an independent prognostic factor.</p><p>After multiple imputations, the mobility QoL scale remained significant despite its high associated relative increase in variance due to missing data imputation. Pain/discomfort was not significant but showed a prognostic value after the multiple- imputation analysis; this may be partially related to the high increase in variance due to missing QoL data.</p><p>We found that the K&#x000f6;hne prognostic system could be improved by including LDH, mobility and pain/discomfort in both complete-case and imputation analyses. Moreover, the GERCOR prognostic index was improved by mobility and anxiety/depression in a complete-case analysis and by ALP, mobility and pain/discomfort after multiple imputations. This difference in the selection of variables may be due to lack of power in the complete-case analysis albeit ALP was at the limit of statistical significance. Therefore the GERCOR prognostic index was essentially improved by QoL scales. The added value of QoL scales (completed by the patient) for improvements of the two prognostic systems revealed that the patient&#x02019;s perception of his/her disease was an important information to record for prognosis assessment in addition to the clinician&#x02019;s evaluation
[<xref ref-type="bibr" rid="B23">23</xref>].</p><p>Despite a marked increase in variance due to missing data, the mobility and pain/discomfort QoL dimensions significantly improved the K&#x000f6;hne and GERCOR staging systems. This result comforted the independent prognostic value of these QoL scales in mCRC patients. The results for complete-case and multiple-imputation analysis were very similar. QoL significantly improved the prognostic indices with both methods (complete-case and multiple-imputation analyses). This may be related to the fact that the compete-case analysis was not biased. In fact, patients with and without QoL data at inclusion did not differ in terms of the median survival time
[<xref ref-type="bibr" rid="B24">24</xref>] (i.e. missingness was not related to outcome).</p><p>It should be noted that such a large improvement in the C-index from 0.54 to 0.66 for the K&#x000f6;hne prognostic index has rarely been reported in prognostic studies. After the addition of both clinical and QoL factors, the NRIs were also statistically significant for both the K&#x000f6;hne and the GERCOR prognostic systems (95% CIs did not contained zero). The independent prognostic value of mobility and pain/discomfort QoL scales (using the EQ-5D) for mCRC is compatible with the result of Efficace
[<xref ref-type="bibr" rid="B12">12</xref>] regarding the prognostic value of social functioning scale (using the EORTC QLQ-C30). In fact, mobility and pain problems could impair the social functioning QoL dimension.</p><p>One of the present study's strengths relates to its use of the easily understood and rapidly completed EQ-5D. The EQ-5D was chosen because it was expected to be less time consuming and could prevent missing data. However, EQ-5D is not a cancer-specific questionnaire like the EORTC QLQ-C30 and it constitutes a limitation of our study. The high proportion of missing data (60%) and its large variability between countries (ranged from 5% to 66%) constitute another limitation in the generalizability of our results. Such a large heterogeneity in missing data might be related to the trial logistic and/or each country&#x02019;s culture. It is also important to note than our population came from a randomized controlled trial with restrictive inclusion and non inclusion criteria and might not be representative of mCRC patients in general
[<xref ref-type="bibr" rid="B25">25</xref>]. Quality of Life may be an important parameter to record when assessing the situation of mCRC patients, since it improved the accuracy of OS prediction and greatly improved the two best-known prognostic classification systems for mCRC. We consider that QoL domains are important factors in the field of stratified therapy in the sense that knowing some aspect of the patient&#x02019;s self-reported QoL level could be decisive in the choice of different treatment options in the area of tailored medicine. By way of an example, a clinician might wish to avoid a treatment with pain as side-effect if the patient reported preexisting pain symptoms. Pain and mobility could also serve as an inclusion and/or stratification factor in randomized, controlled trials in mCRC.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>Our results confirmed the prognostic value of QoL in mCRC patients. Thus, QoL scores should be recorded as it could give supplementary information to the clinician regarding the prognosis of a patient as well as in the judgment of an acceptable treatment side effect.</p></sec><sec><title>Abbreviations</title><p>QoL: Quality of life; mCRC: Metastatic colorectal cancer; OS: Overall survival; EQ-5D: Generic measure of health status developed by the EuroQol Group; HR: Hazard ratio; CI: Confidence interval; CRC: Colorectal cancer; TNM: Tumor Node Metastasis; GERCOR: Groupe Coop&#x000e9;rateur Multidisciplinaire en Oncologie; EORTC: European Organization for Research and Treatment of Cancer; VAS: Visual analogue scale; PS: Performance status; ALP: Alkaline phosphatase; LDH: Lactate dehydrogenase; ITT: Intention to treat; NRI: Net reclassification improvement; CEA: Carcinoembryonic antigen; HDL: High density lipoprotein.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors&#x02019; contributions</title><p>MD, BC, FB, AG, CL, CT, TF, NP, SD, AH, MH and MG the seven authors are justifiably credited with authorship, according to the authorship criteria. In detail: MD BC TF FB &#x02013; conception, design, analysis and interpretation of data, drafting of the manuscript, final approval given; AG CL CT SD NP AH MH MG BC &#x02013; acquisition of data, interpretation of data, critical revision of manuscript, final approval given. All authors read and approved the final manuscript.</p></sec><sec><title>Acknowledgements</title><p>The authors thank Dr. David Fraser for advice in English language.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1</title><p>Results of the multivariate analysis after QoL imputation.</p></caption><media xlink:href="1477-7525-12-69-S1.doc"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Jemal</surname><given-names>A</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Center</surname><given-names>MM</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Ward</surname><given-names>E</given-names></name><name><surname>Forman</surname><given-names>D</given-names></name><article-title>Global cancer statistics</article-title><source>CA Cancer J Clin</source><year>2011</year><volume>61</volume><fpage>69</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.3322/caac.20107</pub-id><pub-id pub-id-type="pmid">21296855</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Field</surname><given-names>K</given-names></name><name><surname>Lipton</surname><given-names>L</given-names></name><article-title>Metastatic colorectal cancer-past, progress and future</article-title><source>World J Gastroenterol</source><year>2007</year><volume>13</volume><issue>28</issue><fpage>3806</fpage><lpage>3815</lpage><pub-id pub-id-type="pmid">17657834</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Folprecht</surname><given-names>G</given-names></name><name><surname>Grothey</surname><given-names>A</given-names></name><name><surname>Alberts</surname><given-names>S</given-names></name><name><surname>Raab</surname><given-names>HR</given-names></name><name><surname>K&#x000f6;hne</surname><given-names>CH</given-names></name><article-title>Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates</article-title><source>Ann Oncol</source><year>2005</year><volume>16</volume><fpage>1311</fpage><lpage>1319</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdi246</pub-id><pub-id pub-id-type="pmid">15870084</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Jessup</surname><given-names>JM</given-names></name><name><surname>Gunderson</surname><given-names>LL</given-names></name><name><surname>Greene</surname><given-names>FL</given-names></name><name><surname>Washington</surname><given-names>MK</given-names></name><name><surname>Compton</surname><given-names>CC</given-names></name><name><surname>Sobin</surname><given-names>LH</given-names></name><name><surname>Minsky</surname><given-names>B</given-names></name><name><surname>Goldbert</surname><given-names>RM</given-names></name><name><surname>Hamilton</surname><given-names>SR</given-names></name><article-title>Staging System for Colon and Rectal Carcinoma</article-title><source>Ann Surg Oncol</source><year>2010</year><volume>2011</volume><issue>18</issue><fpage>1513</fpage><lpage>1517</lpage></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>K&#x000f6;hne</surname><given-names>CH</given-names></name><name><surname>Cunningham</surname><given-names>D</given-names></name><name><surname>Di Constanzo</surname><given-names>F</given-names></name><name><surname>Glimelius</surname><given-names>B</given-names></name><name><surname>Blijham</surname><given-names>G</given-names></name><name><surname>Aranda</surname><given-names>E</given-names></name><name><surname>Scheithauer</surname><given-names>W</given-names></name><name><surname>Rougier</surname><given-names>P</given-names></name><name><surname>Palmer</surname><given-names>M</given-names></name><name><surname>Wils</surname><given-names>J</given-names></name><name><surname>Baron</surname><given-names>B</given-names></name><name><surname>Pignatti</surname><given-names>F</given-names></name><name><surname>Sch&#x000f6;ffski</surname><given-names>P</given-names></name><name><surname>Micheel</surname><given-names>S</given-names></name><name><surname>Hecker</surname><given-names>H</given-names></name><article-title>Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients</article-title><source>Ann Oncol</source><year>2002</year><volume>13</volume><issue>2</issue><fpage>308</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdf034</pub-id><pub-id pub-id-type="pmid">11886010</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Chibaudel</surname><given-names>B</given-names></name><name><surname>Bonnetain</surname><given-names>F</given-names></name><name><surname>Tournigand</surname><given-names>C</given-names></name><name><surname>Bengrine-Lefevre</surname><given-names>L</given-names></name><name><surname>Teixeira</surname><given-names>L</given-names></name><name><surname>Artru</surname><given-names>P</given-names></name><name><surname>Desram&#x000e9;</surname><given-names>J</given-names></name><name><surname>Larsen</surname><given-names>AK</given-names></name><name><surname>Andr&#x000e9;</surname><given-names>T</given-names></name><name><surname>Louvet</surname><given-names>C</given-names></name><name><surname>de Gramont</surname><given-names>A</given-names></name><article-title>Simplified prognostic model in patients with oxaliplatin-based or irinoecan-based first-line chemotherapy for metastatic colorectal cancer: A GERCOR study</article-title><source>Oncologist</source><year>2011</year><volume>16</volume><issue>9</issue><fpage>1228</fpage><lpage>1238</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.2011-0039</pub-id><pub-id pub-id-type="pmid">21859820</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Harrell</surname><given-names>FE</given-names></name><name><surname>Lee</surname><given-names>KL</given-names></name><name><surname>Mark</surname><given-names>DB</given-names></name><article-title>Tutorial in biostatistics. Multivariable prognostic models issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors</article-title><source>Stat Med</source><year>1996</year><volume>15</volume><fpage>361</fpage><lpage>387</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0258(19960229)15:4&#x0003c;361::AID-SIM168&#x0003e;3.0.CO;2-4</pub-id><pub-id pub-id-type="pmid">8668867</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Montazeri</surname><given-names>A</given-names></name><article-title>Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008</article-title><source>Health Qual Life Outcomes</source><year>2009</year><volume>7</volume><fpage>102</fpage><pub-id pub-id-type="doi">10.1186/1477-7525-7-102</pub-id><pub-id pub-id-type="pmid">20030832</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Quinten</surname><given-names>C</given-names></name><name><surname>Coens</surname><given-names>C</given-names></name><name><surname>Mauer</surname><given-names>M</given-names></name><name><surname>Comte</surname><given-names>S</given-names></name><name><surname>Sprangers</surname><given-names>MA</given-names></name><name><surname>Cleeland</surname><given-names>C</given-names></name><name><surname>Osoba</surname><given-names>D</given-names></name><name><surname>Bjordal</surname><given-names>K</given-names></name><name><surname>Bottomley</surname><given-names>A</given-names></name><collab>EORTC Clinical Groups</collab><article-title>Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials</article-title><source>Lancet Oncol</source><year>2009</year><volume>10</volume><fpage>865</fpage><lpage>871</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(09)70200-1</pub-id><pub-id pub-id-type="pmid">19695956</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Diouf</surname><given-names>M</given-names></name><name><surname>Filleron</surname><given-names>T</given-names></name><name><surname>Barbare</surname><given-names>JC</given-names></name><name><surname>Fin</surname><given-names>L</given-names></name><name><surname>Picard</surname><given-names>C</given-names></name><name><surname>Bouch&#x000e9;</surname><given-names>O</given-names></name><name><surname>Dahan</surname><given-names>L</given-names></name><name><surname>Paoletti</surname><given-names>X</given-names></name><name><surname>Bonnetain</surname><given-names>F</given-names></name><article-title>The added value of quality of life (QoL) for prognoses of overall survival in patients with palliative hepatocellular carcinoma</article-title><source>J Hepatol</source><year>2013</year><volume>58</volume><fpage>509</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2012.11.019</pub-id><pub-id pub-id-type="pmid">23178978</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Braun</surname><given-names>DP</given-names></name><name><surname>Gupta</surname><given-names>D</given-names></name><name><surname>Grutsch</surname><given-names>JF</given-names></name><name><surname>Staren</surname><given-names>ED</given-names></name><article-title>Can changes in health related quality of life scores predict survival in stage III and IV colorectal cancer?</article-title><source>Qual Life Res</source><year>2011</year><volume>9</volume><fpage>62</fpage></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Efficace</surname><given-names>F</given-names></name><name><surname>Innominato</surname><given-names>PF</given-names></name><name><surname>Bjarnason</surname><given-names>G</given-names></name><name><surname>Coens</surname><given-names>C</given-names></name><name><surname>Humblet</surname><given-names>Y</given-names></name><name><surname>Tumolo</surname><given-names>S</given-names></name><name><surname>Genet</surname><given-names>D</given-names></name><name><surname>Tampellini</surname><given-names>M</given-names></name><name><surname>Bottomley</surname><given-names>A</given-names></name><name><surname>Garufi</surname><given-names>C</given-names></name><name><surname>Focan</surname><given-names>C</given-names></name><name><surname>Giacchetti</surname><given-names>S</given-names></name><name><surname>L&#x000e9;vi</surname><given-names>F</given-names></name><collab>Chronotherapy Group of the European Organisation for Research and Treatment of Cancer</collab><article-title>Validation of patient&#x02019;s self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>2020</fpage><lpage>2026</lpage><pub-id pub-id-type="doi">10.1200/JCO.2007.12.3117</pub-id><pub-id pub-id-type="pmid">18421055</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Tournigand</surname><given-names>C</given-names></name><name><surname>Cervantes</surname><given-names>A</given-names></name><name><surname>Figer</surname><given-names>A</given-names></name><name><surname>Lledo</surname><given-names>G</given-names></name><name><surname>Flesch</surname><given-names>M</given-names></name><name><surname>Buyse</surname><given-names>M</given-names></name><name><surname>Mineur</surname><given-names>L</given-names></name><name><surname>Carola</surname><given-names>E</given-names></name><name><surname>Etienne</surname><given-names>PL</given-names></name><name><surname>Rivera</surname><given-names>F</given-names></name><name><surname>Chirivella</surname><given-names>I</given-names></name><name><surname>Perez-Staub</surname><given-names>N</given-names></name><name><surname>Louvet</surname><given-names>C</given-names></name><name><surname>Andr&#x000e9;</surname><given-names>T</given-names></name><name><surname>Tabah-Fisch</surname><given-names>I</given-names></name><name><surname>de Gramont</surname><given-names>A</given-names></name><article-title>OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer&#x02014;a GERCOR study</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><fpage>394</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1200/JCO.2005.03.0106</pub-id><pub-id pub-id-type="pmid">16421419</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Group</surname><given-names>EQ</given-names></name><article-title>EuroQol &#x02013; a new facility for the measurement of health-related quality of life</article-title><source>Health Policy</source><year>1990</year><volume>16</volume><fpage>199</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">10109801</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Schemper</surname><given-names>M</given-names></name><article-title>Predictive accuracy and explained variation</article-title><source>Stat Med</source><year>2003</year><volume>22</volume><fpage>2299</fpage><lpage>2308</lpage><pub-id pub-id-type="doi">10.1002/sim.1486</pub-id><pub-id pub-id-type="pmid">12854094</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Pencina</surname><given-names>MJ</given-names></name><name><surname>D&#x02019;Agostino</surname><given-names>RB</given-names></name><name><surname>Steyerberg</surname><given-names>EW</given-names></name><article-title>Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers</article-title><source>Stat Med</source><year>2011</year><volume>30</volume><fpage>11</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1002/sim.4085</pub-id><pub-id pub-id-type="pmid">21204120</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>CLARK</surname><given-names>TG</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><article-title>Developing a prognostic model in presence of missing data: an ovarian cancer study</article-title><source>J Clin Epidemiol</source><year>2003</year><volume>56</volume><fpage>28</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/S0895-4356(02)00539-5</pub-id><pub-id pub-id-type="pmid">12589867</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Marshall</surname><given-names>M</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Royston</surname><given-names>P</given-names></name><name><surname>Holder</surname><given-names>RL</given-names></name><article-title>Comparaison of techniques for handling missing covariate data within prognostic modelling studies: a simulation study</article-title><source>BMC Med Res Methodol</source><year>2010</year><volume>10</volume><fpage>7</fpage><pub-id pub-id-type="doi">10.1186/1471-2288-10-7</pub-id><pub-id pub-id-type="pmid">20085642</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Van Buuren</surname><given-names>S</given-names></name><name><surname>Boshuizen</surname><given-names>HC</given-names></name><name><surname>Knook</surname><given-names>DL</given-names></name><article-title>Multiple imputation of missing blood pressure covariates in survival analysis</article-title><source>Stat Med</source><year>1999</year><volume>18</volume><fpage>681</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0258(19990330)18:6&#x0003c;681::AID-SIM71&#x0003e;3.0.CO;2-R</pub-id><pub-id pub-id-type="pmid">10204197</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Marshall</surname><given-names>M</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Holder</surname><given-names>RL</given-names></name><name><surname>Royston</surname><given-names>P</given-names></name><article-title>Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelines</article-title><source>BMC Med Res Methodol</source><year>2009</year><volume>9</volume><fpage>57</fpage><pub-id pub-id-type="doi">10.1186/1471-2288-9-57</pub-id><pub-id pub-id-type="pmid">19638200</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Tournoux-Facon</surname><given-names>C</given-names></name><name><surname>Paoletti</surname><given-names>X</given-names></name><name><surname>Barbare</surname><given-names>JC</given-names></name><name><surname>Bouch&#x000e9;</surname><given-names>O</given-names></name><name><surname>Rougier</surname><given-names>P</given-names></name><name><surname>Dahan</surname><given-names>L</given-names></name><name><surname>Lombard-Bohas</surname><given-names>C</given-names></name><name><surname>Faroux</surname><given-names>R</given-names></name><name><surname>Raoul</surname><given-names>JL</given-names></name><name><surname>Bedenne</surname><given-names>L</given-names></name><name><surname>Bonnetain</surname><given-names>F</given-names></name><article-title>Development and validation of a new prognostic score of death for patients with hepatocellular carcinoma in palliative setting</article-title><source>J Hepatol</source><year>2011</year><volume>54</volume><issue>1</issue><fpage>108</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2010.06.015</pub-id><pub-id pub-id-type="pmid">21047696</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Kaplan</surname><given-names>EL</given-names></name><name><surname>Meier</surname><given-names>P</given-names></name><article-title>Non parametric estimation from incomplete observations</article-title><source>J Am Stat Assoc</source><year>1958</year><volume>53</volume><fpage>457</fpage><lpage>481</lpage><pub-id pub-id-type="doi">10.1080/01621459.1958.10501452</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Mauer</surname><given-names>M</given-names></name><name><surname>Bottomley</surname><given-names>A</given-names></name><name><surname>Coens</surname><given-names>C</given-names></name><name><surname>Gotay</surname><given-names>C</given-names></name><article-title>Prognostic factor analysis of health-related quality of life data in cancer: statistical methodological evaluation</article-title><source>Expert Rev Pharmacoecon Outcomes Res</source><year>2008</year><volume>8</volume><issue>2</issue><fpage>179</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1586/14737167.8.2.179</pub-id><pub-id pub-id-type="pmid">20528407</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="book"><name><surname>Vach</surname><given-names>W</given-names></name><name><surname>Blettner</surname><given-names>M</given-names></name><article-title>Missing data in epidemiologic studies</article-title><source>Encyclopedia of Biostatistics</source><year>1998</year><publisher-name>New York: John Wiley &#x00026; Sons</publisher-name><fpage>2641</fpage><lpage>2654</lpage></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Moons</surname><given-names>KGM</given-names></name><name><surname>Royston</surname><given-names>P</given-names></name><name><surname>Vergouwe</surname><given-names>Y</given-names></name><name><surname>Grobbee</surname><given-names>DE</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><article-title>Prognosis and prognostic research: what, why, and how?</article-title><source>Br Med J</source><year>2009</year><volume>338</volume><fpage>b375</fpage><comment>1317-1320</comment><pub-id pub-id-type="doi">10.1136/bmj.b375</pub-id><pub-id pub-id-type="pmid">19237405</pub-id></mixed-citation></ref></ref-list></back></article>